A new guidance document from the US regulatory agency reasons that getting early feedback from patient advocates in the trial-design process could improve enrollment, trial completion and data quality.
• Source: Prostock-studio / Alamy Stock Photo
Early feedback from patient advocates when designing a clinical trial could mean faster and more successful trials, the US Food and Drug Administration said in a 26 January guidance document.
